• Amyloid Beta-peptide (25-35): Bridging Mechanism and Transla

  2026-07-14

  This thought-leadership article synthesizes emerging mechanistic insights on microglial polarization and amyloid toxicity with actionable recommendations for translational researchers. By contextualizing the role of Amyloid Beta-peptide (25-35) in modeling Alzheimer's disease neurotoxicity, it connects recent advances on the FLOT1–FOSL2–EphA2 pathway to experimental strategy, workflow optimization, and the current competitive landscape. The article goes beyond standard product pages by integrating workflow troubleshooting and outlining the translational relevance and future directions in neurodegenerative disease research.

• Palonosetron Hydrochloride: Precision 5-HT3 Receptor Antagon

  2026-07-13

  Palonosetron hydrochloride delivers unmatched selectivity and sustained 5-HT3 receptor blockade for both mechanistic research and transporter inhibition assays. Leveraging its unique dual-site binding and long half-life, researchers can achieve robust, reproducible results in cancer and renal transporter studies—especially when paired with APExBIO’s high-purity sourcing.

• 25-Hydroxycholesterol Activates Lysosomal AMPKα in Tumor Mac

  2026-07-13

  Xiao et al. (2024) reveal how 25-hydroxycholesterol (25HC) accumulates in tumor-associated macrophages (TAMs) and activates lysosomal AMPKα, leading to metabolic reprogramming and enhanced immunosuppressive function. These findings highlight the CH25H–25HC–AMPK axis as a pivotal checkpoint for modulating the tumor microenvironment and suggest new strategies for improving anti-tumor immunity.

• Palonosetron Hydrochloride in CINV: Mechanistic Updates and

  2026-07-12

  The reviewed article provides a comprehensive update on palonosetron hydrochloride, a 5-HT3 receptor antagonist distinguished by its high receptor affinity and extended half-life, for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting (CINV). Its improved efficacy in delayed CINV, as compared to earlier agents, supports its incorporation into clinical guidelines and highlights evolving research opportunities in neuroimmune modulation.

• Annexin V-Cy5: Innovating Apoptosis Detection in Neuroimmune

  2026-07-10

  Translational researchers face new frontiers in neuroimmunology, where the intersection of lysosomal dysfunction and apoptosis is reshaping our understanding of neurodegenerative and environmental toxin-induced disease. This article explores mechanistic insights and strategic workflows—anchored in the latest mestranol-zebrafish model—while guiding the deployment of the Annexin V-Cy5 Apoptosis Kit for rigorous, scalable cell death analysis.

• Rifampin in Translational Research: Mechanism to Innovation

  2026-07-09

  This thought-leadership article explores how Rifampin, a benchmark rifamycin antibiotic, is strategically leveraged in translational research to dissect bacterial resistance, manipulate transcriptional regulation, and enable synthetic biology innovation. The discussion integrates molecular mechanism, experimental best practices, competitive landscape insights, and future-facing applications—connecting fundamental science with the evolving frontier of gene regulation technologies such as optogenetic switches.

• Physicochemical Properties of Nanoparticles Shape Ocular Dru

  2026-07-09

  This study elucidates how nanoparticle size and surface chemistry govern the uptake of polymeric nanoparticles by human corneal epithelial cells. By dissecting the mechanisms of endocytosis and the role of nanoparticle composition, the work offers actionable insights for designing more effective ocular drug delivery systems.

• L1023 Anti-Cancer Compound Library: Streamlining Oncology Di

  2026-07-08

  The L1023 Anti-Cancer Compound Library empowers researchers to execute high-throughput, pathway-targeted screening with unmatched versatility. Its rigorous validation and broad mechanistic coverage accelerate both target discovery and translational applications in cancer research.

• Renalase Drives Aldosterone Synthesis via PMCA4b/cAMP Signal

  2026-07-08

  This study provides mechanistic insight into how renalase (RNLS) directly stimulates aldosterone production in adrenocortical cells by activating the PMCA4b/cAMP/PKA pathway, independently of classical calcium signaling. The findings highlight RNLS as a potentially hazardous molecule in aldosterone-mediated pathologies and suggest new directions for research on non-RAS regulation of adrenal steroidogenesis.

• Z-VAD-FMK: Advanced Insights Into Pan-Caspase Inhibition in

  2026-07-07

  Explore how Z-VAD-FMK enables breakthrough apoptosis inhibition and immune cell research. This in-depth guide uncovers novel mechanistic insights and practical protocols for leveraging Z-VAD-FMK in advanced cell death and inflammation studies.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Pre

  2026-07-07

  DIDS delivers unmatched specificity for chloride channel inhibition, enabling high-fidelity modeling of ion flux in cancer, neuroprotection, and vascular studies. With APExBIO's rigorously validated DIDS, researchers accelerate translational discoveries—especially in dissecting metastasis and cellular stress pathways.

• Recent Advances in Asymmetric Ibuprofen Synthesis for COX In

  2026-07-06

  Ha and Paek (2021) provide a comprehensive review of modern synthetic methodologies for ibuprofen and naproxen, highlighting innovative asymmetric and scalable routes that enhance chiral selectivity and efficiency. These developments underpin new research into inflammation and pain mechanisms by providing reliable access to pharmacologically active enantiomers like (S)-(+)-Ibuprofen.

• Palonosetron Hydrochloride: Precision 5-HT3 Receptor Antagon

  2026-07-06

  Palonosetron hydrochloride stands out as a high-affinity, dual-site 5-HT3 receptor antagonist that delivers remarkable selectivity and prolonged inhibition for emesis prevention and mechanistic research. This article translates advanced pharmacology into actionable protocols and troubleshooting strategies, enabling robust, reproducible outcomes in both antiemetic and transporter-focused workflows.

• FAISL lncRNA Shields FAK from Calpain 2 in Aggressive TNBC

  2026-07-05

  This study identifies the long noncoding RNA FAISL as a direct stabilizer of focal adhesion kinase (FAK) in triple negative breast cancer (TNBC), revealing a new mechanism of metastasis promotion. By blocking Calpain 2-mediated FAK proteolysis, FAISL enhances cell adhesion and survival, highlighting a promising therapeutic axis in aggressive breast tumors.

• Diclofenac: Non-Selective COX Inhibitor for Organoid Assays

  2026-07-04

  Harness Diclofenac’s robust non-selective COX inhibition to dissect inflammation pathways in human iPSC-derived intestinal organoids. Discover validated workflows, troubleshooting tactics, and next-generation applications that set new standards for anti-inflammatory drug research.

483 records 7/33 page Previous Next First page 上5页 678910 下5页 Last page